Saturday, October 3, 2026

CBOE Volatility Index Bearish Momentum: 3.62% Down Since The Last Session

ViaNews Editorial Team

January 8, 2021

CBOE Volatility Index Bearish Momentum: 3.62% Down Since The Last Session

CBOE Volatility Index is currently on bearish momentum. At 17:36 EST on Friday, 8 January, CBOE Volatility Index is at $21.56, 3.62% down since the last session's close.

CBOE Volatility Index Range

CBOE Volatility Index is 3.101% down from its last session low of $22.25 and 9.829% down from its last session high of $23.91.

Over the last three sessions, CBOE Volatility Index's higher value was $28.60 and the lower value was $22.14.

Over the last seven sessions, CBOE Volatility Index's higher value was $29.19 and the lower value was $20.99.

Over the last month, CBOE Volatility Index's higher value was $31.46 and the lower value was $20.10.

In relation to CBOE Volatility Index's yearly highs and lows, it's 83.489% up from its 52-week low and 74.775% down from its 52-week high.

Volatility

CBOE Volatility Index's last day, last week, and last month's average volatility was a negative 12.07%, a negative 0.22%, and a positive 0.32%, respectively.

CBOE Volatility Index's last day, last week, and last month's high and low average amplitude percentage was 7.46%, 16.51%, and 11.32%, respectively.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com